Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Late stage Parkinson disease Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Selegiline is an irreversible inhibitor of monoamine oxidase (MAO), an intracellular enzyme associated with the outer membrane of mitochondria.”
“The mean elimination half-life of an intravenous 10 mg dose of selegiline is 1.6 ± 0.3 hours. The half-life of an oral 10 mg dose of selegiline is 1.2 - 1.8 hours.”
“In vitro studies indicate that CYP2B6 is the main hepatic cytochrome P450 (CYP) enzyme involved in the metabolism of selegiline with a possible contribution of CYP3A4 and CP2A6.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.